Quantification of heterogeneity in human CD8+ T cell responses to vaccine antigens: an HLA-guided perspective

Duane C Harris,Apoorv Shanker,Makaela M Montoya,Trent R Llewellyn,Anna R Matuszak,Aditi Lohar,Jessica Z Kubicek Sutherland,Ying Wai Li,Kristen Wilding,Ben Mcmahon,Sandrasegaram Gnanakaran,Ruy M Ribeiro,Alan S Perelson,carmen molina-paris

DOI: https://doi.org/10.1101/2024.07.02.601716

2024-07-03

Abstract:Vaccines have historically played a pivotal role in controlling epidemics. Effective vaccines for viruses causing significant human disease, e.g., Ebola, Lassa fever, or Crimean Congo hemorrhagic fever virus, would be invaluable to public health strategies and counter-measure development missions. Here, we propose coverage metrics to quantify vaccine-induced CD8^+T~cell-mediated immune protection, as well as metrics to characterize immuno-dominant epitopes, in light of human genetic heterogeneity and viral evolution. Proof-of-principle of our approach and methods will be demonstrated for Ebola virus, SARS-CoV-2, and Burkholderia pseudomallei (vaccine) proteins.

Immunology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is about how to quantify the CD8+ T - cell - mediated immune protection induced by vaccines, especially in the context of human genetic heterogeneity and virus evolution. Specifically, the authors proposed a method to define new metrics to quantify the coverage of CD8+ T cells on vaccine proteins and identify immunodominant epitopes. These metrics take the following aspects into account:

1. **Viral genetic diversity**: Evaluate the viral genetic diversity by analyzing the HLA (human leukocyte antigen) allele frequencies in populations from different geographical locations and the binding of these alleles to viral peptides.

2. **HLA variation**: Consider the frequency differences of HLA alleles in different geographical regions and the distribution of these alleles within specific regions to reflect the HLA genetic heterogeneity in the population.

3. **Interaction between peptides and TCR (T - cell receptor)**: Evaluate the immunogenicity of peptide segments by calculating the binding scores between peptide segments and TCR, thereby reflecting the recognition ability of CD8+ T cells to peptide segments.

To achieve this goal, the authors introduced a multi - partite graph model, which contains four different node sets:
- **Geographical regions ()**: Different geographical regions around the world.
- **HLA alleles ()**: Different types of HLA alleles in the population.
- **Peptide segments ()**: 9 - amino - acid - long peptide segments extracted from vaccine proteins.
- **TCR molecular structures ()**: Different TCR molecular structures.

Through this model, the authors defined the following metrics:
- **Mean Regional Coverage Metric (𝑘)**: Used to quantify the overall binding ability of HLA alleles to vaccine protein peptide segments within a certain region.
- **Individual Regional Coverage Metric ((𝑘)
𝑞)**: Used to evaluate the binding ability of individuals with specific HLA allele pairs to vaccine protein peptide segments within a certain region.

In addition, the authors also proposed methods to measure immunodominant epitopes, which dominate the CD8+ T - cell response and are helpful for identifying and predicting virus escape mutations.

In summary, the main goal of this paper is to develop a systematic method to optimize the CD8+ T - cell - mediated vaccine coverage and identify key immunodominant epitopes by considering human genetic heterogeneity and virus evolution. This will be helpful for designing more effective vaccines and reducing the possibility of virus escape.